EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access

Weekly Cisplatin Cycles and Outcomes for Chemoradiation in Head and Neck Cancer

Sung Jun Ma, Simeng Zhu, Jas Virk, Andrew Koempel, Priyanka Bhateja, Emile Gogineni, Sujith Baliga, David Konieczkowski, Darrion Mitchell, Sachin Jhawar, John Grecula, Matthew Old und 3 weitere

JAMA Network Open · 2024

DOI: 10.1001/jamanetworkopen.2024.50272 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift JAMA Network Open, 2024. Verfasst von Sung Jun Ma und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, The Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University Comprehensi…. Hauptthemen laut MEDLINE: Cisplatin, Chemoradiotherapy, Head and Neck Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance National Comprehensive Cancer Network guidelines recommend weekly cisplatin as an alternative concurrent systemic therapy for definitive chemoradiation in patients with head and neck cancer. However, the impact of different levels of adherence to weekly cisplatin on outcomes stratified by human papillomavirus p16 status remains unclear.

Objective

To evaluate the association between the number of weekly cisplatin cycles and outcomes. Design, Setting, and Participants This retrospective, observational, single-institution cohort study at The Ohio State Comprehensive Cancer Center included patients with a diagnosis of nonmetastatic head and neck cancer between December 1, 2011, and March 30, 2020, who received chemoradiation. Data analysis was performed between March and May 2024. Exposure A total of 5, 6, or 7 to 8 weekly cisplatin cycles. Main Outcomes and Measures The primary outcomes were overall survival (OS), progression-free survival (PFS), locoregional failure (LRF), and distant failure (DF). Cox multivariable analysis was performed for variables associated with OS and PFS, and Fine-Gray multivariable analysis was performed for variables associated with LRF and DF.

Results

A total of 142 patients met the criteria (119 men [83.8%]; median [IQR] age, 59 [54-63] years). Median (IQR) follow-up was 46.8 (40.8-55.6) months. Among 92 patients with reasons for cisplatin interruption reported, the most common reason was low blood counts (42 patients [45.7%]). Those who missed weekly cisplatin cycles had worse OS (adjusted hazard ratio [aHR], 2.22; 95% CI, 1.19-4.17; P = .01) and PFS (aHR, 1.83; 95% CI, 1.06-3.15; P = .03) than those who received 7 to 8 cycles. Cancer control outcomes were comparable between these groups (LRF aHR, 0.53; 95% CI, 0.15-1.93; P = .34; DF aHR, 1.51; 95% CI, 0.60-3.82; P = .38). Patients with p16-negative tumors who missed weekly cisplatin cycles had worse OS (for every missing cisplatin cycle, aHR, 11.34, 1.51-84.94; P = .02) than those treated with 7 to 8 cycles. However, for those with p16-positive tumors, there were no statistically significant differences in OS between those who missed weekly cisplatin cycles vs others who received 7 to 8 cycles (aHR, 1.21; 95% CI, 0.47-3.14; P = .69). Conclusions and Relevance In this cohort study of patients with head and neck cancer who received definitive chemoradiation, those with p16-negative tumors who missed weekly cisplatin cycles had lower OS than those who received 7 to 8 cycles, although OS was comparable between these groups for p16-positive tumors. Cytopenia represented the most common reason for cisplatin interruption.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CisplatinChemoradiotherapyHead and Neck NeoplasmsHumansMaleFemaleMiddle AgedRetrospective StudiesAntineoplastic AgentsAgedTreatment OutcomeDrug Administration Schedule

Substanzen

CisplatinAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Radiation Oncology, The Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University Comprehensive Cancer Center, Columbus.
  • Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, The State University of New York, Buffalo.
  • Department of Medical Oncology, The Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University Comprehensive Cancer Center, Columbus.
  • Department of Otolaryngology, The Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University Comprehensive Cancer Center, Columbus.

Förderung

  • NCI NIH HHS

Zitieren

APA

Ma, S. J., Zhu, S., Virk, J., Koempel, A., Bhateja, P., Gogineni, E., Baliga, S., Konieczkowski, D., Mitchell, D., Jhawar, S., Grecula, J., Old, M., Rocco, J., Bonomi, M., & Blakaj, D. (2024). Weekly Cisplatin Cycles and Outcomes for Chemoradiation in Head and Neck Cancer. JAMA Network Open. https://doi.org/10.1001/jamanetworkopen.2024.50272

Vancouver

Ma SJ, Zhu S, Virk J, Koempel A, Bhateja P, Gogineni E, et al. Weekly Cisplatin Cycles and Outcomes for Chemoradiation in Head and Neck Cancer. JAMA Network Open. 2024. doi:10.1001/jamanetworkopen.2024.50272

BibTeX
@article{Ma2024,
  author = {Ma, Sung Jun and Zhu, Simeng and Virk, Jas and Koempel, Andrew and Bhateja, Priyanka and Gogineni, Emile and Baliga, Sujith and Konieczkowski, David and Mitchell, Darrion and Jhawar, Sachin and Grecula, John and Old, Matthew and Rocco, James and Bonomi, Marcelo and Blakaj, Dukagjin},
  title = {Weekly Cisplatin Cycles and Outcomes for Chemoradiation in Head and Neck Cancer},
  journal = {JAMA Network Open},
  year = {2024},
  doi = {10.1001/jamanetworkopen.2024.50272}
}
Kostenlos starten →